Retatrutide and CagriSema are both investigational obesity drugs that outperform current medications in trials, and neither is FDA approved or available by prescription, from TrimRx or anywhere else, as of mid-2026. The headline difference is design and magnitude: retatrutide is a single molecule hitting three receptors and has produced about 28% weight loss, while CagriSema combines two drugs (semaglutide plus an amylin analog) and produced about 22.7%. Both are nearing FDA decisions expected around late 2026. Here is how they compare on mechanism, results, timeline, and what it means while you wait.<\/p>\n
| <\/th>\n | Retatrutide<\/th>\n | CagriSema<\/th>\n<\/tr>\n<\/thead>\n |
|---|---|---|
| Maker<\/td>\n | Eli Lilly<\/td>\n | Novo Nordisk<\/td>\n<\/tr>\n |
| Design<\/td>\n | Single molecule, 3 receptors<\/td>\n | Two drugs combined in one shot<\/td>\n<\/tr>\n |
| Targets<\/td>\n | GLP-1 + GIP + glucagon<\/td>\n | GLP-1 (semaglutide) + amylin (cagrilintide)<\/td>\n<\/tr>\n |
| Trial weight loss<\/td>\n | ~28%<\/td>\n | ~22.7%<\/td>\n<\/tr>\n |
| Status<\/td>\n | Phase 3, NDA expected late 2026<\/td>\n | NDA filed Dec 2025, decision late 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n Retatrutide is a tri-agonist: one engineered peptide that activates three hormone pathways at once. CagriSema takes a different route, pairing two separate molecules (the GLP-1 drug semaglutide, already approved as Wegovy, and cagrilintide, an experimental amylin analog) in a single weekly injection.<\/p>\n Mechanism: glucagon vs amylin<\/h3>\nBoth drugs use GLP-1 to reduce appetite. The difference is the second and third mechanisms. Retatrutide adds GIP (a second incretin) and glucagon; the glucagon piece is notable because it raises energy expenditure and pushes the liver to burn fat, which may explain retatrutide’s larger weight loss. CagriSema adds amylin, a hormone that signals fullness through the brainstem, layering a second satiety signal on top of GLP-1.<\/p>\n Neither is “better” in the abstract; they reflect two bets on how to push weight loss past what single drugs achieve.<\/p>\n Results: retatrutide leads, with caveats<\/h3>\nOn magnitude, retatrutide is ahead. In its Phase 3 trials it has produced roughly 28% average weight loss (about 28.3% at 80 weeks in its largest study, and 28.7% at 68 weeks in another). CagriSema produced about 22.7% in adherent participants over 68 weeks in REDEFINE 1.<\/p>\n Comparing across separate trials is not the same as a head-to-head, so treat the gap as directional rather than exact. Different trials enroll different people and measure outcomes in different ways. Still, the pattern is consistent: retatrutide’s triple mechanism has produced the highest weight-loss numbers of any obesity drug in late-stage testing, and CagriSema, while strong, sits a step below (and notably came in under Novo Nordisk’s own pre-trial projection of around 25%).<\/p>\n Timeline: both close, neither here<\/h3>\nThis is where the two converge. CagriSema is slightly ahead on paperwork: Novo Nordisk filed for FDA approval in December 2025, with a decision expected in late 2026. Retatrutide is a bit behind, with its application expected around late 2026. If all goes well, either could launch in 2027.<\/p>\n Until then, both are investigational. Neither can be prescribed or compounded, and neither is available from TrimRx. Any “retatrutide” or “CagriSema” sold online is not the real, regulated medication, and research-grade peptides carry real risks because they skip the quality, sterility, and dosing oversight that approved drugs require.<\/p>\n Side effects<\/h3>\nBoth are gastrointestinal-forward, like the rest of the class: nausea, constipation, diarrhea, and vomiting, mostly during dose escalation. One difference worth noting is that retatrutide’s glucagon activity modestly raises resting heart rate, a trade-off being studied in its ongoing cardiovascular outcomes trial. CagriSema’s side-effect profile looks much like semaglutide’s, since semaglutide is half of the combination.<\/p>\n Which matters more for you?<\/h3>\nConsider a scenario where someone is trying to decide which future drug to hold out for. The honest answer is that you do not have to pick yet, because neither is available, and both are likely a year or more from pharmacies. The more useful move is to start an approved medication now if you are a candidate. Tirzepatide already produces around 20% weight loss<\/a>, and semaglutide<\/a> is a well-established option, both delivered as regulated, prescribed products. Both work by slowing digestion and curbing appetite<\/a> through the same GLP-1 pathway these newer drugs build on.<\/p>\n |